ADARx Grants CFO Ryan Fisk 170,692 Stock Options

One-fourth of the CFO and CBO's option award vests and becomes exercisable on September 24, 2027, subject to continued service.

Rhea-AI Filing Summary

ADARx Pharmaceuticals, Inc. reported that CFO and CBO Ryan Fisk received a direct grant of options covering 170,692 common shares on September 24, 2026, with a $17 exercise price. One-fourth of the shares vest and become exercisable on September 24, 2027; the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to his continued service on each vesting date. The options expire September 23, 2036.

Insider Trade Summary

Grant/Award: 170,692 shares

Grant/Award 1 txn

Insider Fisk Ryan

Role CFO and CBO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) F1	170,692	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 170,692 contracts (Direct)

Footnotes (1)

1. F1. 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Key Figures

Options granted: 170,692 options covering common shares Exercise price: $17 per share Initial vesting portion: One-fourth of the shares +1 more

4 metrics

Options granted 170,692 options covering common shares Direct award to Ryan Fisk on September 24, 2026

Exercise price $17 per share Employee stock options awarded September 24, 2026

Initial vesting portion One-fourth of the shares Vests and becomes exercisable September 24, 2027, subject to continued service

Option expiration September 23, 2036 Expiration date for the option award

Key Terms

Employee Stock Option (right to buy), exercise price, equal quarterly installments

3 terms

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy)"

exercise price financial

"options have an exercise price of $17"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equal quarterly installments financial

"vest and become exercisable in equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did Ryan Fisk receive from ADARx Pharmaceuticals (ADRX)?

CFO and CBO Ryan Fisk received options covering 170,692 common shares on September 24, 2026, with a $17 exercise price.

When do Ryan Fisk's ADARx (ADRX) options vest?

One-fourth of the shares vest and become exercisable on September 24, 2027. The remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to his continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 08:35 PM Accepted by SEC EDGAR 09/28/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fisk Ryan

(Last) (First) (Middle)

C/O ADARX PHARMACEUTICALS, INC.

5871 OBERLIN DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADARx Pharmaceuticals, Inc. [ ADRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and CBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$17	09/24/2026		A		170,692		(1)	09/23/2036	Common Stock	170,692	$0	170,692	D

Explanation of Responses:

1. 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

	/s/ Jiang Bian, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)